Multilingual medical knowledge
Learn through connected concepts.
Read structured pages, revise high-yield exam points, remember difficult topics and follow recent advances—connected through one node.
Knowledge nodeAMW
Page · Exam · Memory · Advance · Image · Question · Graph
Browse knowledge
Browse all →Subjects and learning paths
Published subject collections will appear here.
Recently published
View all pages →Continue learning
Adrenergic beta-3 Receptor Antagonists
Read pageCholinergic Agonists
Read pageNicotinic Agonists
Read pageMuscarinic Antagonists
Read pageCholinesterase Inhibitors
Read pageAcetylcholine Release Inhibitors
Read pageAngiotensin Receptor Antagonists
Read pageRenin Inhibitors
Read pageThiazide and Related Diuretics
Read pageAdrenergic beta-1 Receptor Antagonists
Read pageCholinergic Agents
Read pageExam
Browse all →Exam revision
Adrenergic beta-1 Receptor Antagonists: classification
Beta-1-selective blockers preferentially antagonize cardiac and renal beta-1 receptors. Selectivity is relative and diminishes as dose increases.
OpenAdrenergic beta-1 Receptor Antagonists: mechanism
Beta-1-selective blockers preferentially antagonize cardiac and renal beta-1 receptors. Selectivity is relative and diminishes as dose increases.
OpenAdrenergic beta-1 Receptor Antagonists: safety
Bradycardia, hypotension, fatigue and conduction block. Pulmonary risk is lower than with nonselective agents but is not absent.
OpenMemory
Browse all →Memory corner
Adrenergic beta-1 Receptor Antagonists: classification
Representative beta-1-selective blockers include metoprolol, atenolol, bisoprolol, esmolol and nebivolol. Selectivity is dose-dependent rather than absolute.
OpenAdrenergic beta-1 Receptor Antagonists: mechanism
Beta-1-selective blockers preferentially antagonize cardiac and renal beta-1 receptors. Selectivity is relative and diminishes as dose increases.
OpenAdrenergic beta-2 Receptor Antagonists: classification
Selective beta-2 antagonists do not form a major routine therapeutic drug class. Beta-2 blockade is encountered chiefly as part of nonselective beta-blocker pharmacology.
OpenAdvance
Browse all →Recent advances
Nothing published here yet.
On this device
Open your library →Recently viewed
Pages and learning items you open will appear here.